FKBPs in chromatin modification and cancer
FKBPs in chromatin modification and cancer
复制标题
DOI：
10.1016/j.coph.2011.03.005
复制
发表时间：
2011-08-01
影响因子：
4
通讯作者：
Yang, Wen-Ming
中科院分区：
文献类型：
--
作者：
Yao, Ya-Li;Liang, Ya-Chen;Yang, Wen-Ming
FK506结合蛋白（FKBP）是FK506和雷帕霉素的细胞内受体，雷帕霉素是最近被用作抗癌药物的免疫抑制剂。在细胞质中，FKBP和这些药物调节信号转导途径。然而，最近的报道揭示了FKBPs在细胞核中的新功能，包括调节转录因子，组蛋白伴侣活性和染色质结构的修饰。已知这些活动会影响基因表达、DNA修复和DNA复制。因此，阐明FKBPs的核功能将有助于研究人员和临床医生更好地了解免疫抑制剂如何作为抗癌药物发挥作用，这反过来可能导致癌症治疗的新设计。
FK506-binding proteins (FKBPs) are intracellular receptors for FK506 and rapamycin, immunosuppressants that have recently been utilized as anticancer drugs. In the cytoplasm, FKBPs and these drugs modulate signal transduction pathways. However, recent reports reveal novel functions of FKBPs in the nucleus, which include regulation of transcription factors, histone chaperone activity, and modifications of chromatin structure. These activities are known to affect gene expression, DNA repair, and DNA replication. Therefore, elucidation of the nuclear functions of FKBPs will help researchers and clinicians better understand how immunosuppressants work as anticancer drugs, which might in turn lead to novel designs of cancer therapy.